# Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection

> **NCT03847376** · — · APPROVED_FOR_MARKETING · sponsor: **Janssen Sciences Ireland UC**

## Conditions studied

- HIV

## Interventions

- **DRUG:** Rilpivirine Long Acting (RPV LA)

## Key facts

- **NCT ID:** NCT03847376
- **Lead sponsor:** Janssen Sciences Ireland UC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03847376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03847376, "Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03847376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*